Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Semin Neurol 2013; 33(04): 386-416
DOI: 10.1055/s-0033-1359312
DOI: 10.1055/s-0033-1359312
Neuroimaging Biomarkers of Neurodegenerative Diseases and Dementia
Further Information
Publication History
Publication Date:
14 November 2013 (online)
Abstract
Neurodegenerative disorders leading to dementia are common diseases that affect many older and some young adults. Neuroimaging methods are important tools for assessing and monitoring pathological brain changes associated with progressive neurodegenerative conditions. In this review, the authors describe key findings from neuroimaging studies (magnetic resonance imaging and radionucleotide imaging) in neurodegenerative disorders, including Alzheimer's disease (AD) and prodromal stages, familial and atypical AD syndromes, frontotemporal dementia, amyotrophic lateral sclerosis with and without dementia, Parkinson's disease with and without dementia, dementia with Lewy bodies, Huntington's disease, multiple sclerosis, HIV-associated neurocognitive disorder, and prion protein associated diseases (i.e., Creutzfeldt-Jakob disease). The authors focus on neuroimaging findings of in vivo pathology in these disorders, as well as the potential for neuroimaging to provide useful information for differential diagnosis of neurodegenerative disorders.
Keywords
neuroimaging - dementia - Alzheimer's disease (AD) - mild cognitive impairment (MCI) - frontotemporal dementia (FTD) - amyotrophic lateral sclerosis (ALS) - dementia with Lewy bodies (DLB) - Parkinson's disease (PD) - Huntington's disease (HD) - multiple sclerosis (MS) - HIV-associated neurocognitive disorder (HAND) - Cruetzfeldt-Jakob disease (CJD) - Gerstmann-Straussler-Scheinker disease (GSS)-
References
- 1 Letourneau-Guillon L, Wada R, Kucharczyk W. Imaging of prion diseases. J Magn Reson Imaging 2012; 35 (5) 998-1012
- 2 Politis M, Piccini P. Positron emission tomography imaging in neurological disorders. J Neurol 2012; 259 (9) 1769-1780
- 3 Alzheimer's Association. Facts and Figures. Chicago, IL: Alzheimer's Association; 2012
- 4 McKhann gmatter, Knopman DS, Chertkow H , et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 263-269
- 5 Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56 (3) 303-308
- 6 Albert MS, DeKosky ST, Dickson D , et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 270-279
- 7 Sperling RA, Aisen PS, Beckett LA , et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7 (3) 280-292
- 8 Jack Jr CR, Knopman DS, Jagust WJ , et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9 (1) 119-128
- 9 Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33 (6) 403-408
- 10 Bateman RJ, Xiong C, Benzinger TL , et al; Dominantly Inherited Alzheimer Network. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012; 367 (9) 795-804
- 11 McGinnis SM. Neuroimaging in neurodegenerative dementias. Semin Neurol 2012; 32 (4) 347-360
- 12 Andrade K, Kas A, Valabrègue R , et al. Visuospatial deficits in posterior cortical atrophy: structural and functional correlates. J Neurol Neurosurg Psychiatry 2012; 83 (9) 860-863
- 13 Rohrer JD. Structural brain imaging in frontotemporal dementia. Biochim Biophys Acta 2012; 1822 (3) 325-332
- 14 Viswanathan A, Greenberg SM. Cerebral amyloid angiopathy in the elderly. Ann Neurol 2011; 70 (6) 871-880
- 15 Kinnecom C, Lev MH, Wendell L , et al. Course of cerebral amyloid angiopathy-related inflammation. Neurology 2007; 68 (17) 1411-1416
- 16 Grossman M. Biomarkers to identify the pathological basis for frontotemporal lobar degeneration. J Mol Neurosci 2011; 45 (3) 366-371
- 17 Whitwell JL, Josephs KA. Neuroimaging in frontotemporal lobar degeneration–predicting molecular pathology. . Nat Rev Neurology 2011; 8 (3) 131-142
- 18 Lomen-Hoerth C. Clinical phenomenology and neuroimaging correlates in ALS-FTD. J Mol Neurosci 2011; 45 (3) 656-662
- 19 Trojsi F, Monsurrò MR, Esposito F, Tedeschi G. Widespread structural and functional connectivity changes in amyotrophic lateral sclerosis: insights from advanced neuroimaging research. Neural Plast 2012; 2012: 473538
- 20 Watson R, Blamire AM, O'Brien JT. Magnetic resonance imaging in Lewy body dementias. Dement Geriatr Cogn Disord 2009; 28 (6) 493-506
- 21 Silbert LC, Kaye J. Neuroimaging and cognition in Parkinson's disease dementia. Brain Pathol 2010; 20 (3) 646-653
- 22 Papp KV, Kaplan RF, Snyder PJ. Biological markers of cognition in prodromal Huntington's disease: a review. Brain Cogn 2011; 77 (2) 280-291
- 23 Sá MJ. Physiopathology of symptoms and signs in multiple sclerosis. Arq Neuropsiquiatr 2012; 70 (9) 733-740
- 24 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372 (9648) 1502-1517
- 25 Nakahara J, Maeda M, Aiso S, Suzuki N. Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy. Clin Rev Allergy Immunol 2012; 42 (1) 26-34
- 26 Lublin FD, Reingold SC ; National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996; 46 (4) 907-911
- 27 Antinori A, Arendt G, Becker JT , et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007; 69 (18) 1789-1799
- 28 Tozzi V, Balestra P, Lorenzini P , et al. Prevalence and risk factors for human immunodeficiency virus-associated neurocognitive impairment, 1996 to 2002: results from an urban observational cohort. J Neurovirol 2005; 11 (3) 265-273
- 29 Bonnet F, Amieva H, Marquant F , et al; S CO3 Aquitaine Cohort. Cognitive disorders in HIV-infected patients: are they HIV-related?. AIDS 2013; 27 (3) 391-400
- 30 Steinbrink F, Evers S, Buerke B , et al; German Competence Network HIV/AIDS. Cognitive impairment in HIV infection is associated with MRI and CSF pattern of neurodegeneration. Eur J Neurol 2013; 20 (3) 420-428
- 31 Robertson K, Liner J, Heaton R. Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev 2009; 19 (2) 232-249
- 32 Alsop DC, Dai W, Grossman M, Detre JA. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J Alzheimers Dis 2010; 20 (3) 871-880
- 33 Wang Y, Saykin AJ, Pfeuffer J , et al. Regional reproducibility of pulsed arterial spin labeling perfusion imaging at 3T. Neuroimage 2011; 54 (2) 1188-1195
- 34 Ogawa S, Tank DW, Menon R , et al. Intrinsic signal changes accompanying sensory stimulation: functional brain mapping with magnetic resonance imaging. Proc Natl Acad Sci U S A 1992; 89 (13) 5951-5955
- 35 Logothetis NK, Pauls J, Augath M, Trinath T, Oeltermann A. Neurophysiological investigation of the basis of the fMRI signal. Nature 2001; 412 (6843) 150-157
- 36 Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci U S A 2003; 100 (1) 253-258
- 37 Jack Jr CR, Bernstein MA, Borowski BJ , et al; Alzheimer's Disease Neuroimaging Initiative. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative. Alzheimers Dement 2010; 6 (3) 212-220
- 38 Weiner MW, Veitch DP, Aisen PS , et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement 2013; Sept; 9 (5) e111-e194
- 39 Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC ; Alzheimer's Disease Neuroimaging Initiative (ADNI). Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res 2009; 6 (4) 347-361
- 40 Du AT, Schuff N, Amend D , et al. Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease. J Neurol Neurosurg Psychiatry 2001; 71 (4) 441-447
- 41 Chételat G, Desgranges B, De La Sayette V, Viader F, Eustache F, Baron JC. Mapping gray matter loss with voxel-based morphometry in mild cognitive impairment. Neuroreport 2002; 13 (15) 1939-1943
- 42 Hämäläinen A, Tervo S, Grau-Olivares M , et al. Voxel-based morphometry to detect brain atrophy in progressive mild cognitive impairment. Neuroimage 2007; 37 (4) 1122-1131
- 43 Whitwell JL, Shiung MM, Przybelski SA , et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70 (7) 512-520
- 44 deToledo-Morrell L, Stoub TR, Bulgakova M , et al. MRI-derived entorhinal volume is a good predictor of conversion from MCI to AD. Neurobiol Aging 2004; 25 (9) 1197-1203
- 45 Devanand DP, Liu X, Tabert MH , et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease. Biol Psychiatry 2008; 64 (10) 871-879
- 46 Jack Jr CR, Petersen RC, Xu YC , et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 1999; 52 (7) 1397-1403
- 47 Barnes J, Bartlett JW, van de Pol LA , et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009; 30 (11) 1711-1723
- 48 Honea RA, Vidoni E, Harsha A, Burns JM. Impact of APOE on the healthy aging brain: a voxel-based MRI and DTI study. J Alzheimers Dis 2009; 18 (3) 553-564
- 49 Risacher SL, Shen L, West JD , et al; Alzheimer's Disease Neuroimaging Initiative (ADNI). Longitudinal MRI atrophy biomarkers: relationship to conversion in the ADNI cohort. Neurobiol Aging 2010; 31 (8) 1401-1418
- 50 Donix M, Burggren AC, Suthana NA , et al. Longitudinal changes in medial temporal cortical thickness in normal subjects with the APOE-4 polymorphism. Neuroimage 2010; 53 (1) 37-43
- 51 Wishart HA, Saykin AJ, McAllister TW , et al. Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 2006; 67 (7) 1221-1224
- 52 Chételat G, Villemagne VL, Bourgeat P , et al; Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010; 67 (3) 317-324
- 53 Bourgeat P, Chételat G, Villemagne VL , et al; AIBL Research Group. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology 2010; 74 (2) 121-127
- 54 Jack Jr CR, Lowe VJ, Senjem ML , et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131 (Pt 3) 665-680
- 55 Saykin AJ, Wishart HA, Rabin LA , et al. Older adults with cognitive complaints show brain atrophy similar to that of amnestic MCI. Neurology 2006; 67 (5) 834-842
- 56 Scheef L, Spottke A, Daerr M , et al. Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology 2012; 79 (13) 1332-1339
- 57 Striepens N, Scheef L, Wind A , et al. Volume loss of the medial temporal lobe structures in subjective memory impairment. Dement Geriatr Cogn Disord 2010; 29 (1) 75-81
- 58 Ibrahim I, Horacek J, Bartos A , et al. Combination of voxel based morphometry and diffusion tensor imaging in patients with Alzheimer's disease. Neuroendocrinol Lett 2009; 30 (1) 39-45
- 59 Rose SE, McMahon KL, Janke AL , et al. Diffusion indices on magnetic resonance imaging and neuropsychological performance in amnestic mild cognitive impairment. J Neurol Neurosurg Psychiatry 2006; 77 (10) 1122-1128
- 60 Zhang Y, Schuff N, Jahng GH , et al. Diffusion tensor imaging of cingulum fibers in mild cognitive impairment and Alzheimer disease. Neurology 2007; 68 (1) 13-19
- 61 Fellgiebel A, Wille P, Müller MJ , et al. Ultrastructural hippocampal and white matter alterations in mild cognitive impairment: a diffusion tensor imaging study. Dement Geriatr Cogn Disord 2004; 18 (1) 101-108
- 62 Wang Y, West JD, Flashman LA , et al. Selective changes in white matter integrity in MCI and older adults with cognitive complaints. Biochim Biophys Acta 2012; 1822 (3) 423-430
- 63 Chantal S, Braun CM, Bouchard RW, Labelle M, Boulanger Y. Similar 1H magnetic resonance spectroscopic metabolic pattern in the medial temporal lobes of patients with mild cognitive impairment and Alzheimer disease. Brain Res 2004; 1003 (1-2) 26-35
- 64 Schuff N, Capizzano AA, Du AT , et al. Selective reduction of N-acetylaspartate in medial temporal and parietal lobes in AD. Neurology 2002; 58 (6) 928-935
- 65 Kantarci K, Jack Jr CR, Xu YC , et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer's disease: A 1H MRS study. Neurology 2000; 55 (2) 210-217
- 66 Harris GJ, Lewis RF, Satlin A , et al. Dynamic susceptibility contrast MR imaging of regional cerebral blood volume in Alzheimer disease: a promising alternative to nuclear medicine. AJNR Am J Neuroradiol 1998; 19 (9) 1727-1732
- 67 Celone KA, Calhoun VD, Dickerson BC , et al. Alterations in memory networks in mild cognitive impairment and Alzheimer's disease: an independent component analysis. J Neurosci 2006; 26 (40) 10222-10231
- 68 Dickerson BC, Salat DH, Greve DN , et al. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005; 65 (3) 404-411
- 69 Johnson SC, Schmitz TW, Moritz CH , et al. Activation of brain regions vulnerable to Alzheimer's disease: the effect of mild cognitive impairment. Neurobiol Aging 2006; 27 (11) 1604-1612
- 70 Trivedi MA, Murphy CM, Goetz C , et al. fMRI activation changes during successful episodic memory encoding and recognition in amnestic mild cognitive impairment relative to cognitively healthy older adults. Dement Geriatr Cogn Disord 2008; 26 (2) 123-137
- 71 Saykin AJ, Flashman LA, Frutiger SA , et al. Neuroanatomic substrates of semantic memory impairment in Alzheimer's disease: patterns of functional MRI activation. J Int Neuropsychol Soc 1999; 5 (5) 377-392
- 72 Pariente J, Cole S, Henson R , et al. Alzheimer's patients engage an alternative network during a memory task. Ann Neurol 2005; 58 (6) 870-879
- 73 O'Brien JL, O'Keefe KM, LaViolette PS , et al. Longitudinal fMRI in elderly reveals loss of hippocampal activation with clinical decline. Neurology 2010; 74 (24) 1969-1976
- 74 Bookheimer SY, Strojwas MH, Cohen MS , et al. Patterns of brain activation in people at risk for Alzheimer's disease. N Engl J Med 2000; 343 (7) 450-456
- 75 Johnson SC, Schmitz TW, Trivedi MA , et al. The influence of Alzheimer disease family history and apolipoprotein E epsilon4 on mesial temporal lobe activation. J Neurosci 2006; 26 (22) 6069-6076
- 76 Wishart HA, Saykin AJ, Rabin LA , et al. Increased brain activation during working memory in cognitively intact adults with the APOE epsilon4 allele. Am J Psychiatry 2006; 163 (9) 1603-1610
- 77 Johnson SC, Saykin AJ, Baxter LC , et al. The relationship between fMRI activation and cerebral atrophy: comparison of normal aging and Alzheimer disease. Neuroimage 2000; 11 (3) 179-187
- 78 Grady CL, McIntosh AR, Beig S, Keightley ML, Burian H, Black SE. Evidence from functional neuroimaging of a compensatory prefrontal network in Alzheimer's disease. J Neurosci 2003; 23 (3) 986-993
- 79 Zhou Y, Dougherty Jr JH, Hubner KF, Bai B, Cannon RL, Hutson RK. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement 2008; 4 (4) 265-270
- 80 Buckner RL, Snyder AZ, Shannon BJ , et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25 (34) 7709-7717
- 81 Greicius MD, Srivastava G, Reiss AL, Menon V. Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI. Proc Natl Acad Sci U S A 2004; 101 (13) 4637-4642
- 82 Bai F, Zhang Z, Watson DR , et al. Abnormal functional connectivity of hippocampus during episodic memory retrieval processing network in amnestic mild cognitive impairment. Biol Psychiatry 2009; 65 (11) 951-958
- 83 Sperling RA, Laviolette PS, O'Keefe K , et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron 2009; 63 (2) 178-188
- 84 Rami L, Sala-Llonch R, Solé-Padullés C , et al. Distinct functional activity of the precuneus and posterior cingulate cortex during encoding in the preclinical stage of Alzheimer's disease. J Alzheimers Dis 2012; 31 (3) 517-526
- 85 Trachtenberg AJ, Filippini N, Ebmeier KP, Smith SM, Karpe F, Mackay CE. The effects of APOE on the functional architecture of the resting brain. Neuroimage 2012; 59 (1) 565-572
- 86 Wang Y, Risacher SL, West JD , et al. Altered default mode network connectivity in older adults with cognitive complaints and amnestic mild cognitive impairment. J Alzheimers Dis 2013; 35 (4) 751-760
- 87 Langbaum JB, Chen K, Lee W , et al; Alzheimer's Disease Neuroimaging Initiative. Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage 2009; 45 (4) 1107-1116
- 88 Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005; 32 (4) 486-510
- 89 Herholz K, Nordberg A, Salmon E , et al. Impairment of neocortical metabolism predicts progression in Alzheimer's disease. Dement Geriatr Cogn Disord 1999; 10 (6) 494-504
- 90 Alexander GE, Chen K, Pietrini P, Rapoport SI, Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002; 159 (5) 738-745
- 91 Small GW, Ercoli LM, Silverman DH , et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2000; 97 (11) 6037-6042
- 92 de Leon MJ, Convit A, Wolf OT , et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A 2001; 98 (19) 10966-10971
- 93 Mosconi L, De Santi S, Brys M , et al. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints. Biol Psychiatry 2008; 63 (6) 609-618
- 94 Klunk WE, Engler H, Nordberg A , et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004; 55 (3) 306-319
- 95 Jack Jr CR, Lowe VJ, Weigand SD , et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132 (Pt 5) 1355-1365
- 96 Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain imaging in Alzheimer disease. Cold Spring Harb Perspect Med 2012; 2 (4) a006213
- 97 Forsberg A, Engler H, Almkvist O , et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008; 29 (10) 1456-1465
- 98 Klunk WE, Mathis CA, Price JC, Lopresti BJ, DeKosky ST. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129 (Pt 11) 2805-2807
- 99 Reiman EM, Chen K, Liu X , et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009; 106 (16) 6820-6825
- 100 Honea RA, Vidoni ED, Swerdlow RH, Burns JM ; Alzheimer's Disease Neuroimaging Initiative. Maternal family history is associated with Alzheimer's disease biomarkers. J Alzheimers Dis 2012; 31 (3) 659-668
- 101 Mosconi L, Rinne JO, Tsui WH , et al. Increased fibrillar amyloid-beta burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci U S A 2010; 107 (13) 5949-5954
- 102 Rowe CC, Ellis KA, Rimajova M , et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010; 31 (8) 1275-1283
- 103 Clark CM, Schneider JA, Bedell BJ , et al; AV45-A07 Study Group. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305 (3) 275-283
- 104 Rinne JO, Kaasinen V, Järvenpää T , et al. Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer's disease. J Neurol Neurosurg Psychiatry 2003; 74 (1) 113-115
- 105 Herholz K, Weisenbach S, Kalbe E, Diederich NJ, Heiss WD. Cerebral acetylcholine esterase activity in mild cognitive impairment. Neuroreport 2005; 16 (13) 1431-1434
- 106 Sabri O, Kendziorra K, Wolf H, Gertz HJ, Brust P. Acetylcholine receptors in dementia and mild cognitive impairment. Eur J Nucl Med Mol Imaging 2008; 35 (Suppl. 01) S30-S45
- 107 Pappatà S, Salvatore E, Postiglione A. In vivo imaging of neurotransmission and brain receptors in dementia. J Neuroimaging 2008; 18 (2) 111-124
- 108 Hasselbalch SG, Madsen K, Svarer C , et al. Reduced 5-HT2A receptor binding in patients with mild cognitive impairment. Neurobiol Aging 2008; 29 (12) 1830-1838
- 109 Edison P, Archer HA, Gerhard A , et al. Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiol Dis 2008; 32 (3) 412-419
- 110 Okello A, Edison P, Archer HA , et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009; 72 (1) 56-62
- 111 Wiley CA, Lopresti BJ, Venneti S , et al. Carbon 11-labeled Pittsburgh compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009; 66 (1) 60-67
- 112 Ringman JM, O'Neill J, Geschwind D , et al. Diffusion tensor imaging in preclinical and presymptomatic carriers of familial Alzheimer's disease mutations. Brain 2007; 130 (Pt 7) 1767-1776
- 113 Ringman JM, Younkin SG, Pratico D , et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008; 71 (2) 85-92
- 114 Fox NC, Warrington EK, Freeborough PA , et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996; 119 (Pt 6) 2001-2007
- 115 Gregory GC, Macdonald V, Schofield PR, Kril JJ, Halliday gmatter. Differences in regional brain atrophy in genetic forms of Alzheimer's disease. Neurobiol Aging 2006; 27 (3) 387-393
- 116 Bateman RJ, Aisen PS, De Strooper B , et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011; 3 (1) 1
- 117 Villemagne VL, Ataka S, Mizuno T , et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol 2009; 66 (12) 1537-1544
- 118 Migliaccio R, Agosta F, Scola E , et al. Ventral and dorsal visual streams in posterior cortical atrophy: a DT MRI study. Neurobiol Aging 2012; 33 (11) 2572-2584
- 119 Lehmann M, Crutch SJ, Ridgway GR , et al. Cortical thickness and voxel-based morphometry in posterior cortical atrophy and typical Alzheimer's disease. Neurobiol Aging 2011; 32 (8) 1466-1476
- 120 de Souza LC, Lehéricy S, Dubois B, Stella F, Sarazin M. Neuroimaging in dementias. Curr Opin Psychiatry 2012; 25 (6) 473-479
- 121 Kas A, de Souza LC, Samri D , et al. Neural correlates of cognitive impairment in posterior cortical atrophy. Brain 2011; 134 (Pt 5) 1464-1478
- 122 Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Arch Neurol 2007; 64 (8) 1140-1144
- 123 Madhavan A, Whitwell JL, Weigand SD , et al. FDG PET and MRI in logopenic primary progressive aphasia versus dementia of the Alzheimer's type. PLoS ONE 2013; 8 (4) e62471
- 124 Mahoney CJ, Malone IB, Ridgway GR , et al. White matter tract signatures of the progressive aphasias. Neurobiol Aging 2013; 34 (6) 1687-1699
- 125 Magnin E, Cattin F, Vandel P, Galmiche J, Moulin T, Rumbach L. Fractional anisotropy in three variants of primary progressive aphasia. Eur Neurol 2012; 68 (4) 229-233
- 126 Rabinovici GD, Jagust WJ, Furst AJ , et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol 2008; 64 (4) 388-401
- 127 Wattjes MP. Structural MRI. Int Psychogeriatr 2011; Sept; 23 (Suppl. 02) S13-S24
- 128 Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging in dementia. Neurotherapeutics 2011; 8 (1) 82-92
- 129 Dumas A, Dierksen GA, Gurol ME , et al. Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann Neurol 2012; 72 (1) 76-81
- 130 Chung YA, , O JH, Kim JY. , et al. Hypoperfusion and ischemia in cerebral amyloid angiopathy documented by 99mTc-ECD brain perfusion SPECT. J Nucl Med 2009; 50 (12) 1969-1974
- 131 Villemagne VL, Rowe CC. Amyloid imaging. Int Psychogeriatr 2011; Sept; 23 (Suppl. 02) S41-S49
- 132 Du AT, Schuff N, Laakso MP , et al. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neurology 2002; 58 (11) 1635-1641
- 133 Eckerström C, Olsson E, Klasson N , et al. High white matter lesion load is associated with hippocampal atrophy in mild cognitive impairment. Dement Geriatr Cogn Disord 2011; 31 (2) 132-138
- 134 Fein G, Di Sclafani V, Tanabe J , et al. Hippocampal and cortical atrophy predict dementia in subcortical ischemic vascular disease. Neurology 2000; 55 (11) 1626-1635
- 135 Jagust WJ, Zheng L, Harvey DJ , et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol 2008; 63 (1) 72-80
- 136 Mungas D, Jagust WJ, Reed BR , et al. MRI predictors of cognition in subcortical ischemic vascular disease and Alzheimer's disease. Neurology 2001; 57 (12) 2229-2235
- 137 Scher AI, Xu Y, Korf ES , et al. Hippocampal morphometry in population-based incident Alzheimer's disease and vascular dementia: the HAAS. J Neurol Neurosurg Psychiatry 2011; 82 (4) 373-376
- 138 Mori E. Impact of subcortical ischemic lesions on behavior and cognition. Ann N Y Acad Sci 2002; 977: 141-148
- 139 van de Pol LA, Korf ES, van der Flier wmatter , et al. Magnetic resonance imaging predictors of cognition in mild cognitive impairment. Arch Neurol 2007; 64 (7) 1023-1028
- 140 Verdelho A, Madureira S, Moleiro C , et al; LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: the LADIS study. Neurology 2010; 75 (2) 160-167
- 141 Cho H, Kwon JH, Seo HJ. Medial temporal lobe atrophy in vascular dementia: visual temporal lobe rating scale. Arch Gerontol Geriatr 2009; 48 (3) 415-418
- 142 Li C, Du H, Zheng J, Wang J. A voxel-based morphometric analysis of cerebral gray matter in subcortical ischemic vascular dementia patients and normal aged controls. Int J Med Sci 2011; 8 (6) 482-486
- 143 Seo SW, Ahn J, Yoon U , et al. Cortical thinning in vascular mild cognitive impairment and vascular dementia of subcortical type. J Neuroimaging 2010; 20 (1) 37-45
- 144 van de Pol L, Gertz HJ, Scheltens P, Wolf H. Hippocampal atrophy in subcortical vascular dementia. Neurodegener Dis 2011; 8 (6) 465-469
- 145 Chen Y, Chen X, Xiao W, Mok VC, Wong KS, Tang WK. Frontal lobe atrophy is associated with small vessel disease in ischemic stroke patients. Clin Neurol Neurosurg 2009; 111 (10) 852-857
- 146 Looi JC, Tatham V, Kumar R , et al. Caudate nucleus volumes in stroke and vascular dementia. Psychiatry Res 2009; 174 (1) 67-75
- 147 Chen TF, Lin CC, Chen YF , et al. Diffusion tensor changes in patients with amnesic mild cognitive impairment and various dementias. Psychiatry Res 2009; 173 (1) 15-21
- 148 Della Nave R, Foresti S, Pratesi A , et al. Whole-brain histogram and voxel-based analyses of diffusion tensor imaging in patients with leukoaraiosis: correlation with motor and cognitive impairment. AJNR Am J Neuroradiol 2007; 28 (7) 1313-1319
- 149 Fu JL, Zhang T, Chang C, Zhang YZ, Li WB. The value of diffusion tensor imaging in the differential diagnosis of subcortical ischemic vascular dementia and Alzheimer's disease in patients with only mild white matter alterations on T2-weighted images. Acta Radiol 2012; 53 (3) 312-317
- 150 Kim SH, Park JS, Ahn HJ , et al. Voxel-based analysis of diffusion tensor imaging in patients with subcortical vascular cognitive impairment: correlates with cognitive and motor deficits. J Neuroimaging 2011; 21 (4) 317-324
- 151 Nitkunan A, Barrick TR, Charlton RA, Clark CA, Markus HS. Multimodal MRI in cerebral small vessel disease: its relationship with cognition and sensitivity to change over time. Stroke 2008; 39 (7) 1999-2005
- 152 O'Sullivan M, Morris RG, Huckstep B, Jones DK, Williams SC, Markus HS. Diffusion tensor MRI correlates with executive dysfunction in patients with ischaemic leukoaraiosis. J Neurol Neurosurg Psychiatry 2004; 75 (3) 441-447
- 153 O'Sullivan M, Summers PE, Jones DK, Jarosz JM, Williams SC, Markus HS. Normal-appearing white matter in ischemic leukoaraiosis: a diffusion tensor MRI study. Neurology 2001; 57 (12) 2307-2310
- 154 Xu Q, Zhou Y, Li YS , et al. Diffusion tensor imaging changes correlate with cognition better than conventional MRI findings in patients with subcortical ischemic vascular disease. Dement Geriatr Cogn Disord 2010; 30 (4) 317-326
- 155 Li C, Zheng J, Wang J, Gui L. Comparison between Alzheimer's disease and subcortical vascular dementia: attentional cortex study in functional magnetic resonance imaging. J Int Med Res 2011; 39 (4) 1413-1419
- 156 Tak S, Yoon SJ, Jang J, Yoo K, Jeong Y, Ye JC. Quantitative analysis of hemodynamic and metabolic changes in subcortical vascular dementia using simultaneous near-infrared spectroscopy and fMRI measurements. Neuroimage 2011; 55 (1) 176-184
- 157 Sun YW, Qin LD, Zhou Y , et al. Abnormal functional connectivity in patients with vascular cognitive impairment, no dementia: a resting-state functional magnetic resonance imaging study. Behav Brain Res 2011; 223 (2) 388-394
- 158 Schuff N, Matsumoto S, Kmiecik J , et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 2009; 5 (6) 454-462
- 159 Pakrasi S, O'Brien JT. Emission tomography in dementia. Nucl Med Commun 2005; 26 (3) 189-196
- 160 Powers WJ, Zazulia AR. PET in Cerebrovascular Disease. PET Clin 2010; 5 (1) 83106
- 161 Heiss WD, Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci 2012; 322 (1-2) 268-273
- 162 Yoon CW, Shin JS, Kim HJ , et al. Cognitive deficits of pure subcortical vascular dementia vs. Alzheimer disease: PiB-PET-based study. Neurology 2013; 80 (6) 569-573
- 163 Piguet O, Hornberger M, Mioshi E, Hodges JR. Behavioural-variant frontotemporal dementia: diagnosis, clinical staging, and management. Lancet Neurol 2011; 10 (2) 162-172
- 164 Seelaar H, Rohrer JD, Pijnenburg YA, Fox NC, van Swieten JC. Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a review. J Neurol Neurosurg Psychiatry 2011; 82 (5) 476-486
- 165 Krueger CE, Dean DL, Rosen HJ , et al. Longitudinal rates of lobar atrophy in frontotemporal dementia, semantic dementia, and Alzheimer's disease. Alzheimer Dis Assoc Disord 2010; 24 (1) 43-48
- 166 Whitwell JL, Jack Jr CR, Parisi JE , et al. Imaging signatures of molecular pathology in behavioral variant frontotemporal dementia. J Mol Neurosci 2011; 45 (3) 372-378
- 167 Whitwell JL, Josephs KA, Rossor MN , et al. Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia. Arch Neurol 2005; 62 (9) 1402-1408
- 168 Ghetti B, Spina S, Murrell JR , et al. In vivo and postmortem clinicoanatomical correlations in frontotemporal dementia and parkinsonism linked to chromosome 17. Neurodegener Dis 2008; 5 (3-4) 215-217
- 169 Whitwell JL, Przybelski SA, Weigand SD , et al. Distinct anatomical subtypes of the behavioural variant of frontotemporal dementia: a cluster analysis study. Brain 2009; 132 (Pt 11) 2932-2946
- 170 Whitwell JL, Jack Jr CR, Parisi JE , et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration?. Neurology 2010; 75 (24) 2212-2220
- 171 Rohrer JD, Geser F, Zhou J , et al. TDP-43 subtypes are associated with distinct atrophy patterns in frontotemporal dementia. Neurology 2010; 75 (24) 2204-2211
- 172 Rohrer JD, Lashley T, Schott JM , et al. Clinical and neuroanatomical signatures of tissue pathology in frontotemporal lobar degeneration. Brain 2011; 134 (Pt 9) 2565-2581
- 173 Josephs KA, Whitwell JL, Parisi JE , et al. Caudate atrophy on MRI is a characteristic feature of FTLD-FUS. Eur J Neurol 2010; 17 (7) 969-975
- 174 Zhang Y, Schuff N, Ching C , et al. Joint assessment of structural, perfusion, and diffusion MRI in Alzheimer's disease and frontotemporal dementia. Int J Alzheimers Dis 2011; 2011: 546871
- 175 Whitwell JL, Avula R, Senjem ML , et al. Gray and white matter water diffusion in the syndromic variants of frontotemporal dementia. Neurology 2010; 74 (16) 1279-1287
- 176 Ebmeier KP, Filippini N, Heise V, Sexton CE. Other magnetic resonance imaging techniques. Int Psychogeriatr 2011; 23 (Suppl. 02) S50-S57
- 177 Dopper EG, Rombouts SA, Jiskoot LC , et al. Structural and functional brain connectivity in presymptomatic familial frontotemporal dementia. Neurology 2013; 80 (9) 814-823
- 178 Rombouts SA, van Swieten JC, Pijnenburg YA, Goekoop R, Barkhof F, Scheltens P. Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. Neurology 2003; 60 (12) 1904-1908
- 179 Virani K, Jesso S, Kertesz A, Mitchell D, Finger E. Functional neural correlates of emotional expression processing deficits in behavioural variant frontotemporal dementia. J Psychiatry Neurosci 2013; 38 (3) 174-182
- 180 Seeley WW, Menon V, Schatzberg AF , et al. Dissociable intrinsic connectivity networks for salience processing and executive control. J Neurosci 2007; 27 (9) 2349-2356
- 181 Pievani M, de Haan W, Wu T, Seeley WW, Frisoni GB. Functional network disruption in the degenerative dementias. Lancet Neurol 2011; 10 (9) 829-843
- 182 Filippi M, Agosta F, Scola E , et al. Functional network connectivity in the behavioral variant of frontotemporal dementia. Cortex 2012;
- 183 Seeley WW, Crawford R, Rascovsky K , et al. Frontal paralimbic network atrophy in very mild behavioral variant frontotemporal dementia. Arch Neurol 2008; 65 (2) 249-255
- 184 Zhou J, Greicius MD, Gennatas ED , et al. Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. Brain 2010; 133 (Pt 5) 1352-1367
- 185 Whitwell JL, Josephs KA, Avula R , et al. Altered functional connectivity in asymptomatic MAPT subjects: a comparison to bvFTD. Neurology 2011; 77 (9) 866-874
- 186 Du AT, Jahng GH, Hayasaka S , et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006; 67 (7) 1215-1220
- 187 Mummery CJ, Patterson K, Price CJ, Ashburner J, Frackowiak RS, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. Ann Neurol 2000; 47 (1) 36-45
- 188 Bonner MF, Vesely L, Price C , et al. Reversal of the concreteness effect in semantic dementia. Cogn Neuropsychol 2009; 26 (6) 568-579
- 189 Hodges JR, Patterson K. Semantic dementia: a unique clinicopathological syndrome. Lancet Neurol 2007; 6 (11) 1004-1014
- 190 Rohrer JD, Warren JD, Modat M , et al. Patterns of cortical thinning in the language variants of frontotemporal lobar degeneration. Neurology 2009; 72 (18) 1562-1569
- 191 Czarnecki K, Duffy JR, Nehl CR , et al. Very early semantic dementia with progressive temporal lobe atrophy: an 8-year longitudinal study. Arch Neurol 2008; 65 (12) 1659-1663
- 192 Maguire EA, Kumaran D, Hassabis D, Kopelman MD. Autobiographical memory in semantic dementia: a longitudinal fMRI study. Neuropsychologia 2010; 48 (1) 123-136
- 193 Goll JC, Ridgway GR, Crutch SJ, Theunissen FE, Warren JD. Nonverbal sound processing in semantic dementia: a functional MRI study. Neuroimage 2012; 61 (1) 170-180
- 194 Wilson SM, Brambati SM, Henry RG , et al. The neural basis of surface dyslexia in semantic dementia. Brain 2009; 132 (Pt 1) 71-86
- 195 Farb NA, Grady CL, Strother S , et al. Abnormal network connectivity in frontotemporal dementia: evidence for prefrontal isolation. Cortex 2013; 49 (7) 1856-1873
- 196 Josephs KA, Duffy JR, Strand EA , et al. Clinicopathological and imaging correlates of progressive aphasia and apraxia of speech. Brain 2006; 129 (Pt 6) 1385-1398
- 197 Peelle JE, Troiani V, Gee J , et al. Sentence comprehension and voxel-based morphometry in progressive nonfluent aphasia, semantic dementia, and nonaphasic frontotemporal dementia. J Neurolinguist 2008; 21 (5) 418-432
- 198 Cooke A, DeVita C, Gee J , et al. Neural basis for sentence comprehension deficits in frontotemporal dementia. Brain Lang 2003; 85 (2) 211-221
- 199 Caso F, Gesierich B, Henry M , et al. Nonfluent/agrammatic PPA with in-vivo cortical amyloidosis and Pick's disease pathology. Behav Neurol 2013; 26 (1-2) 95-106
- 200 Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain 2003; 126 (Pt 11) 2406-2418
- 201 Gil-Navarro S, Lomeña F, Cot A , et al. Decreased striatal dopamine transporter uptake in the non-fluent/agrammatic variant of primary progressive aphasia. Eur J Neurol 2013;
- 202 Josephs KA, Whitwell JL, Dickson DW , et al. Voxel-based morphometry in autopsy proven PSP and CBD. Neurobiol Aging 2008; 29 (2) 280-289
- 203 Whitwell JL, Jack Jr CR, Parisi JE , et al. Rates of cerebral atrophy differ in different degenerative pathologies. Brain 2007; 130 (Pt 4) 1148-1158
- 204 Tokumaru AM, Saito Y, Murayama S , et al. Imaging-pathologic correlation in corticobasal degeneration. AJNR Am J Neuroradiol 2009; 30 (10) 1884-1892
- 205 Erbetta A, Mandelli ML, Savoiardo M , et al. Diffusion tensor imaging shows different topographic involvement of the thalamus in progressive supranuclear palsy and corticobasal degeneration. AJNR Am J Neuroradiol 2009; 30 (8) 1482-1487
- 206 Dashjamts T, Yoshiura T, Hiwatashi A , et al. Asymmetrical cerebral perfusion demonstrated by noninvasive arterial spin-labeling perfusion imaging in a patient with corticobasal degeneration. Jpn J Radiol 2010; 28 (1) 75-78
- 207 Cilia R, Rossi C, Frosini D , et al. Dopamine Transporter SPECT Imaging in Corticobasal Syndrome. PLoS ONE 2011; 6 (5) e18301
- 208 Mazère J, Meissner WG, Mayo W , et al. Progressive supranuclear palsy: in vivo SPECT imaging of presynaptic vesicular acetylcholine transporter with [123I]-iodobenzovesamicol. Radiology 2012; 265 (2) 537-543
- 209 Teune LK, Bartels AL, de Jong BM , et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord 2010; 25 (14) 2395-2404
- 210 Kuwahara H, Tsuchiya K, Saito Y , et al. Frontotemporal lobar degeneration with motor neuron disease showing severe and circumscribed atrophy of anterior temporal lobes. J Neurol Sci 2010; 297 (1-2) 92-96
- 211 Turner MR, Agosta F, Bede P, Govind V, Lulé D, Verstraete E. Neuroimaging in amyotrophic lateral sclerosis. Biomarkers Med 2012; 6 (3) 319-337
- 212 Sage CA, Peeters RR, Görner A, Robberecht W, Sunaert S. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis. Neuroimage 2007; 34 (2) 486-499
- 213 Sage CA, Van Hecke W, Peeters R , et al. Quantitative diffusion tensor imaging in amyotrophic lateral sclerosis: revisited. Hum Brain Mapp 2009; 30 (11) 3657-3675
- 214 Sarro L, Agosta F, Canu E , et al. Cognitive functions and white matter tract damage in amyotrophic lateral sclerosis: a diffusion tensor tractography study. AJNR Am J Neuroradiol 2011; 32 (10) 1866-1872
- 215 Abrahams S, Goldstein LH, Kew JJ , et al. Frontal lobe dysfunction in amyotrophic lateral sclerosis. A PET study. Brain 1996; 119 (Pt 6) 2105-2120
- 216 Abrahams S, Leigh PN, Kew JJ, Goldstein LH, Lloyd CM, Brooks DJ. A positron emission tomography study of frontal lobe function (verbal fluency) in amyotrophic lateral sclerosis. J Neurol Sci 1995; 129 (Suppl): 44-46
- 217 Abrahams S, Goldstein LH, Simmons A , et al. Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain 2004; 127 (Pt 7) 1507-1517
- 218 Palmieri A, Naccarato M, Abrahams S , et al. Right hemisphere dysfunction and emotional processing in ALS: an fMRI study. J Neurol 2010; 257 (12) 1970-1978
- 219 Mohammadi B, Kollewe K, Samii A, Krampfl K, Dengler R, Münte TF. Changes of resting state brain networks in amyotrophic lateral sclerosis. Exp Neurol 2009; 217 (1) 147-153
- 220 Guedj E, Le Ber I, Lacomblez L , et al; French Research Network on FTD/FTD-MND. Brain spect perfusion of frontotemporal dementia associated with motor neuron disease. Neurology 2007; 69 (5) 488-490
- 221 Talbot PR, Goulding PJ, Lloyd JJ, Snowden JS, Neary D, Testa HJ. Inter-relation between “classic” motor neuron disease and frontotemporal dementia: neuropsychological and single photon emission computed tomography study. J Neurol Neurosurg Psychiatry 1995; 58 (5) 541-547
- 222 Ishikawa T, Morita M, Nakano I. Constant blood flow reduction in premotor frontal lobe regions in ALS with dementia - a SPECT study with 3D-SSP. Acta Neurol Scand 2007; 116 (5) 340-344
- 223 Garraux G, Salmon E, Degueldre C, Lemaire C, Franck G. Medial temporal lobe metabolic impairment in dementia associated with motor neuron disease. J Neurol Sci 1999; 168 (2) 145-150
- 224 Jeong Y, Park KC, Cho SS , et al. Pattern of glucose hypometabolism in frontotemporal dementia with motor neuron disease. Neurology 2005; 64 (4) 734-736
- 225 Ludolph AC, Langen KJ, Regard M , et al. Frontal lobe function in amyotrophic lateral sclerosis: a neuropsychologic and positron emission tomography study. Acta Neurol Scand 1992; 85 (2) 81-89
- 226 Lloyd CM, Richardson MP, Brooks DJ, Al-Chalabi A, Leigh PN. Extramotor involvement in ALS: PET studies with the GABA(A) ligand [(11)C]flumazenil. Brain 2000; 123 (Pt 11) 2289-2296
- 227 Sha SJ, Takada LT, Rankin KP , et al. Frontotemporal dementia due to C9ORF72 mutations: clinical and imaging features. Neurology 2012; 79 (10) 1002-1011
- 228 Yokoyama JS, Rosen HJ. Neuroimaging features of C9ORF72 expansion. Alzheimers Res Ther 2012; 4 (6) 45
- 229 Kassubek J, Unrath A, Huppertz HJ , et al. Global brain atrophy and corticospinal tract alterations in ALS, as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6 (4) 213-220
- 230 Chen Z, Ma L. Grey matter volume changes over the whole brain in amyotrophic lateral sclerosis: A voxel-wise meta-analysis of voxel based morphometry studies. Amyotroph Lateral Scler 2010; 11 (6) 549-554
- 231 Roccatagliata L, Bonzano L, Mancardi G, Canepa C, Caponnetto C. Detection of motor cortex thinning and corticospinal tract involvement by quantitative MRI in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2009; 10 (1) 47-52
- 232 Filippini N, Douaud G, Mackay CE, Knight S, Talbot K, Turner MR. Corpus callosum involvement is a consistent feature of amyotrophic lateral sclerosis. Neurology 2010; 75 (18) 1645-1652
- 233 Menke RA, Abraham I, Thiel CS , et al. Fractional anisotropy in the posterior limb of the internal capsule and prognosis in amyotrophic lateral sclerosis. Arch Neurol 2012; 69 (11) 1493-1499
- 234 Li J, Pan P, Song W, Huang R, Chen K, Shang H. A meta-analysis of diffusion tensor imaging studies in amyotrophic lateral sclerosis. Neurobiol Aging 2012; 33 (8) 1833-1838
- 235 Konrad C, Henningsen H, Bremer J , et al. Pattern of cortical reorganization in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Exp Brain Res 2002; 143 (1) 51-56
- 236 Han J, Ma L. Functional magnetic resonance imaging study of the brain in patients with amyotrophic lateral sclerosis. Chin Med Sci J 2006; 21 (4) 228-233
- 237 Stanton BR, Williams VC, Leigh PN , et al. Altered cortical activation during a motor task in ALS. Evidence for involvement of central pathways. J Neurol 2007; 254 (9) 1260-1267
- 238 Konrad C, Jansen A, Henningsen H , et al. Subcortical reorganization in amyotrophic lateral sclerosis. Exp Brain Res 2006; 172 (3) 361-369
- 239 Lulé D, Diekmann V, Müller HP, Kassubek J, Ludolph AC, Birbaumer N. Neuroimaging of multimodal sensory stimulation in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2010; 81 (8) 899-906
- 240 Jelsone-Swain LM, Fling BW, Seidler RD, Hovatter R, Gruis K, Welsh RC. Reduced Interhemispheric Functional Connectivity in the Motor Cortex during Rest in Limb-Onset Amyotrophic Lateral Sclerosis. Front Syst Neurosci 2010; 4: 158
- 241 Agosta F, Valsasina P, Absinta M , et al. Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis. Cereb Cortex 2011; 21 (10) 2291-2298
- 242 Han J, Ma L. Study of the features of proton MR spectroscopy ((1)H-MRS) on amyotrophic lateral sclerosis. J Magn Reson Imaging 2010; 31 (2) 305-308
- 243 Schuff N, Rooney WD, Miller R , et al. Reanalysis of multislice (1)H MRSI in amyotrophic lateral sclerosis. Magn Reson Med 2001; 45 (3) 513-516
- 244 Yin H, Lim CC, Ma L , et al. Combined MR spectroscopic imaging and diffusion tensor MRI visualizes corticospinal tract degeneration in amyotrophic lateral sclerosis. J Neurol 2004; 251 (10) 1249-1254
- 245 Lombardo F, Frijia F, Bongioanni P , et al. Diffusion tensor MRI and MR spectroscopy in long lasting upper motor neuron involvement in amyotrophic lateral sclerosis. Arch Ital Biol 2009; 147 (3) 69-82
- 246 Ludolph AC, Elger CE, Böttger IW, Kuttig AG, Lottes G, Brune GG. N-isopropyl-p-123I-amphetamine single photon emission computer tomography in motor neuron disease. Eur Neurol 1989; 29 (5) 255-260
- 247 Tanaka M, Kondo S, Hirai S, Sun X, Yamagishi T, Okamoto K. Cerebral blood flow and oxygen metabolism in progressive dementia associated with amyotrophic lateral sclerosis. J Neurol Sci 1993; 120 (1) 22-28
- 248 Kew JJ, Goldstein LH, Leigh PN , et al. The relationship between abnormalities of cognitive function and cerebral activation in amyotrophic lateral sclerosis. A neuropsychological and positron emission tomography study. Brain 1993; 116 (Pt 6) 1399-1423
- 249 Takahashi H, Snow BJ, Bhatt MH, Peppard R, Eisen A, Calne DB. Evidence for a dopaminergic deficit in sporadic amyotrophic lateral sclerosis on positron emission scanning. Lancet 1993; 342 (8878) 1016-1018
- 250 Turner MR, Gerhard A, Al-Chalabi A , et al. Mills' and other isolated upper motor neurone syndromes: in vivo study with 11C-(R)-PK11195 PET. J Neurol Neurosurg Psychiatry 2005; 76 (6) 871-874
- 251 Turner MR, Cagnin A, Turkheimer FE , et al. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol Dis 2004; 15 (3) 601-609
- 252 Monchi O, Degroot C, Mejia-Constain B, Bruneau MA. Neuroimaging studies of different cognitive profiles in Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (Suppl. 01) S77-S79
- 253 Tateno M, Kobayashi S, Saito T. Imaging improves diagnosis of dementia with lewy bodies. Psychiatry Investig 2009; 6 (4) 233-240
- 254 Hashimoto M, Kitagaki H, Imamura T , et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies: a volumetric MRI study. Neurology 1998; 51 (2) 357-362
- 255 Burton EJ, Karas G, Paling SM , et al. Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. Neuroimage 2002; 17 (2) 618-630
- 256 Ballmaier M, O'Brien JT, Burton EJ , et al. Comparing gray matter loss profiles between dementia with Lewy bodies and Alzheimer's disease using cortical pattern matching: diagnosis and gender effects. Neuroimage 2004; 23 (1) 325-335
- 257 Burton EJ, McKeith IG, Burn DJ, Williams ED, O'Brien JT. Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain 2004; 127 (Pt 4) 791-800
- 258 Johansen KK, White LR, Sando SB, Aasly JO. Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies. Parkinsonism Relat Disord 2010; 16 (5) 307-315
- 259 Beyer MK, Larsen JP, Aarsland D. Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology 2007; 69 (8) 747-754
- 260 Shimada H, Shinotoh H, Hirano S , et al. β-Amyloid in Lewy body disease is related to Alzheimer's disease-like atrophy. Mov Disord 2013; 28 (2) 169-175
- 261 Burton EJ, McKeith IG, Burn DJ, O'Brien JT. Brain atrophy rates in Parkinson's disease with and without dementia using serial magnetic resonance imaging. Mov Disord 2005; 20 (12) 1571-1576
- 262 O'Brien JT, Paling S, Barber R , et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology 2001; 56 (10) 1386-1388
- 263 Lee JE, Park HJ, Park B , et al. A comparative analysis of cognitive profiles and white-matter alterations using voxel-based diffusion tensor imaging between patients with Parkinson's disease dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 2010; 81 (3) 320-326
- 264 Bozzali M, Cherubini A. Diffusion tensor MRI to investigate dementias: a brief review. Magn Reson Imaging 2007; 25 (6) 969-977
- 265 Bozzali M, Falini A, Cercignani M , et al. Brain tissue damage in dementia with Lewy bodies: an in vivo diffusion tensor MRI study. Brain 2005; 128 (Pt 7) 1595-1604
- 266 Firbank MJ, Blamire AM, Krishnan MS , et al. Atrophy is associated with posterior cingulate white matter disruption in dementia with Lewy bodies and Alzheimer's disease. Neuroimage 2007; 36 (1) 1-7
- 267 Matsui H, Nishinaka K, Oda M, Niikawa H, Kubori T, Udaka F. Dementia in Parkinson's disease: diffusion tensor imaging. Acta Neurol Scand 2007; 116 (3) 177-181
- 268 Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain metabolism differs in Alzheimer's disease and Parkinson's disease dementia. Alzheimers Dement 2008; 4 (6) 421-427
- 269 Griffith HR, den Hollander JA, Okonkwo OC, O'Brien T, Watts RL, Marson DC. Brain N-acetylaspartate is reduced in Parkinson disease with dementia. Alzheimer Dis Assoc Disord 2008; 22 (1) 54-60
- 270 Griffith HR, Okonkwo OC, O'Brien T, Hollander JA. Reduced brain glutamate in patients with Parkinson's disease. NMR Biomed 2008; 21 (4) 381-387
- 271 Sauer J, ffytche DH, Ballard C, Brown RG, Howard R. Differences between Alzheimer's disease and dementia with Lewy bodies: an fMRI study of task-related brain activity. Brain 2006; 129 (Pt 7) 1780-1788
- 272 Taylor JP, Firbank MJ, He J , et al. Visual cortex in dementia with Lewy bodies: magnetic resonance imaging study. Br J Psychiatry 2012; 200 (6) 491-498
- 273 Monchi O, Petrides M, Doyon J, Postuma RB, Worsley K, Dagher A. Neural bases of set-shifting deficits in Parkinson's disease. J Neurosci 2004; 24 (3) 702-710
- 274 Galvin JE, Price JL, Yan Z, Morris JC, Sheline YI. Resting bold fMRI differentiates dementia with Lewy bodies vs Alzheimer disease. Neurology 2011; 76 (21) 1797-1803
- 275 Torosyan N, Silverman DH. Neuronuclear imaging in the evaluation of dementia and mild decline in cognition. Semin Nucl Med 2012; 42 (6) 415-422
- 276 Kantarci K, Lowe VJ, Boeve BF , et al. Multimodality imaging characteristics of dementia with Lewy bodies. Neurobiol Aging 2012; 33 (9) 2091-2105
- 277 Gilman S, Koeppe RA, Little R , et al. Differentiation of Alzheimer's disease from dementia with Lewy bodies utilizing positron emission tomography with [18F]fluorodeoxyglucose and neuropsychological testing. Exp Neurol 2005; 191 (Suppl. 01) S95-S103
- 278 Peppard RF, Martin WR, Carr GD , et al. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992; 49 (12) 1262-1268
- 279 Schapiro MB, Pietrini P, Grady CL , et al. Reductions in parietal and temporal cerebral metabolic rates for glucose are not specific for Alzheimer's disease. J Neurol Neurosurg Psychiatry 1993; 56 (8) 859-864
- 280 Vander Borght T, Minoshima S, Giordani B , et al. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38 (5) 797-802
- 281 O'Brien JT, Colloby S, Fenwick J , et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004; 61 (6) 919-925
- 282 Rinne JO, Portin R, Ruottinen H , et al. Cognitive impairment and the brain dopaminergic system in Parkinson disease: [18F]fluorodopa positron emission tomographic study. Arch Neurol 2000; 57 (4) 470-475
- 283 Brooks DJ, Pavese N. Imaging biomarkers in Parkinson's disease. Prog Neurobiol 2011; 95 (4) 614-628
- 284 Mori T, Maeda J, Shimada H , et al. Molecular imaging of dementia. Psychogeriatrics 2012; 12 (2) 106-114
- 285 Bohnen NI, Kaufer DI, Hendrickson R , et al. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253 (2) 242-247
- 286 Bohnen NI, Kaufer DI, Ivanco LS , et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003; 60 (12) 1745-1748
- 287 Hilker R, Thomas AV, Klein JC , et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65 (11) 1716-1722
- 288 Bouchard TP, Malykhin N, Martin WR , et al. Age and dementia-associated atrophy predominates in the hippocampal head and amygdala in Parkinson's disease. Neurobiol Aging 2008; 29 (7) 1027-1039
- 289 Brück A, Kurki T, Kaasinen V, Vahlberg T, Rinne JO. Hippocampal and prefrontal atrophy in patients with early non-demented Parkinson's disease is related to cognitive impairment. J Neurol Neurosurg Psychiatry 2004; 75 (10) 1467-1469
- 290 Camicioli R, Moore MM, Kinney A, Corbridge E, Glassberg K, Kaye JA. Parkinson's disease is associated with hippocampal atrophy. Mov Disord 2003; 18 (7) 784-790
- 291 Hu MT, White SJ, Chaudhuri KR, Morris RG, Bydder gmatter, Brooks DJ. Correlating rates of cerebral atrophy in Parkinson's disease with measures of cognitive decline. J Neural Transm 2001; 108 (5) 571-580
- 292 Hu MT, Taylor-Robinson SD, Chaudhuri KR , et al. Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain 2000; 123 (Pt 2) 340-352
- 293 Huang C, Tang C, Feigin A , et al. Changes in network activity with the progression of Parkinson's disease. Brain 2007; 130 (Pt 7) 1834-1846
- 294 Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114 (Pt 5) 2283-2301
- 295 Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64 (3) 314-319
- 296 Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993; 8 (2) 134-138
- 297 Sawle GV. The detection of preclinical Parkinson's disease: what is the role of positron emission tomography?. Mov Disord 1993; 8 (3) 271-277
- 298 Kaasinen V, Någren K, Hietala J , et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000; 54 (7) 1482-1487
- 299 Kaasinen V, Aalto S, NAgren K, Hietala J, Sonninen P, Rinne JO. Extrastriatal dopamine D(2) receptors in Parkinson's disease: a longitudinal study. J Neural Transm 2003; 110 (6) 591-601
- 300 Guttman M, Boileau I, Warsh J , et al. Brain serotonin transporter binding in non-depressed patients with Parkinson's disease. Eur J Neurol 2007; 14 (5) 523-528
- 301 Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998; 65 (2) 155-163
- 302 Shtilbans A, Henchcliffe C. Biomarkers in Parkinson's disease: an update. Curr Opin Neurol 2012; 25 (4) 460-465
- 303 Piccini P, Weeks RA, Brooks DJ. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol 1997; 42 (5) 720-726
- 304 Gerhard A, Pavese N, Hotton G , et al. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21 (2) 404-412
- 305 Ouchi Y, Yoshikawa E, Sekine Y , et al. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005; 57 (2) 168-175
- 306 Georgiou-Karistianis N, Scahill R, Tabrizi SJ, Squitieri F, Aylward E. Structural MRI in Huntington's disease and recommendations for its potential use in clinical trials. Neurosci Biobehav Rev 2013; 37 (3) 480-490
- 307 Paulsen JS, Langbehn DR, Stout JC , et al; Predict-HD Investigators and Coordinators of the Huntington Study Group. Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 2008; 79 (8) 874-880
- 308 Paulsen JS, Nopoulos PC, Aylward E , et al; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG). Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010; 82 (3-4) 201-207
- 309 Tabrizi SJ, Langbehn DR, Leavitt BR , et al; TRACK-HD investigators. Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009; 8 (9) 791-801
- 310 Tabrizi SJ, Reilmann R, Roos RA , et al; TRACK-HD investigators. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24. month observational data. Lancet Neurol 2012; 11 (1) 42-53
- 311 Majid DS, Aron AR, Thompson W , et al. Basal ganglia atrophy in prodromal Huntington's disease is detectable over one year using automated segmentation. Mov Disord 2011; 26 (14) 2544-2551
- 312 Tabrizi SJ, Scahill RI, Durr A , et al; TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 2011; 10 (1) 31-42
- 313 Henley SM, Wild EJ, Hobbs NZ , et al. Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease. Mov Disord 2009; 24 (6) 932-936
- 314 Hobbs NZ, Pedrick AV, Say MJ , et al. The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov Disord 2011; 26 (9) 1684-1690
- 315 Rupp J, Dzemidzic M, Blekher T , et al. Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease. J Neurol 2012; 259 (2) 267-276
- 316 Magnotta VA, Kim J, Koscik T , et al. Diffusion Tensor Imaging in Preclinical Huntington's Disease. Brain Imaging Behav 2009; 3 (1) 77-84
- 317 Reading SA, Yassa MA, Bakker A , et al. Regional white matter change in pre-symptomatic Huntington's disease: a diffusion tensor imaging study. Psychiatry Res 2005; 140 (1) 55-62
- 318 Rosas HD, Tuch DS, Hevelone ND , et al. Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures. Mov Disord 2006; Sept; 21 (9) 1317-1325
- 319 Klöppel S, Henley SM, Hobbs NZ , et al. Magnetic resonance imaging of Huntington's disease: preparing for clinical trials. Neuroscience 2009; 164 (1) 205-219
- 320 Rupp J, Dzemidzic M, Blekher T , et al. Abnormal error-related antisaccade activation in premanifest and early manifest Huntington disease. Neuropsychology 2011; 25 (3) 306-318
- 321 Unschuld PG, Joel SE, Liu X , et al. Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci Lett 2012; 514 (2) 204-209
- 322 Wolf RC, Sambataro F, Vasic N , et al. Default-mode network changes in preclinical Huntington's disease. Exp Neurol 2012; 237 (1) 191-198
- 323 Weeks RA, Ceballos-Baumann A, Piccini P, Boecker H, Harding AE, Brooks DJ. Cortical control of movement in Huntington's disease. A PET activation study. Brain 1997; Nov; 120 (Pt 9) 1569-1578
- 324 Feigin A, Leenders KL, Moeller JR , et al. Metabolic network abnormalities in early Huntington's disease: an [(18)F]FDG PET study. J Nucl Med 2001; Nov; 42 (11) 1591-1595
- 325 Ginovart N, Lundin A, Farde L , et al. PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. Brain 1997; 120 (Pt 3) 503-514
- 326 Antonini A, Leenders KL, Eidelberg D. [11C]raclopride-PET studies of the Huntington's disease rate of progression: relevance of the trinucleotide repeat length. Ann Neurol 1998; 43 (2) 253-255
- 327 Andrews TC, Weeks RA, Turjanski N , et al. Huntington's disease progression. PET and clinical observations. Brain 1999; 122 (Pt 12) 2353-2363
- 328 Pavese N, Andrews TC, Brooks DJ , et al. Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain 2003; 126 (Pt 5) 1127-1135
- 329 Pavese N, Politis M, Tai YF , et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2010; 37 (2) 356-361
- 330 Tai YF, Pavese N, Gerhard A , et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72 (2-3) 148-151
- 331 Tai YF, Pavese N, Gerhard A , et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130 (Pt 7) 1759-1766
- 332 Politis M, Pavese N, Tai YF , et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp 2011; 32 (2) 258-270
- 333 Pavese N, Gerhard A, Tai YF , et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 2006; 66 (11) 1638-1643
- 334 Sbardella E, Petsas N, Tona F , et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS ONE 2013; 8 (5) e63250
- 335 Ceccarelli A, Bakshi R, Neema M. MRI in multiple sclerosis: a review of the current literature. Curr Opin Neurol 2012; 25 (4) 402-409
- 336 Filippi M, Rocca MA, De Stefano N , et al. Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch Neurol 2011; 68 (12) 1514-1520
- 337 Rocca MA, Mesaros S, Pagani E, Sormani MP, Comi G, Filippi M. Thalamic damage and long-term progression of disability in multiple sclerosis. Radiology 2010; 257 (2) 463-469
- 338 Sbardella E, Tona F, Petsas N, Pantano P. DTI Measurements in Multiple Sclerosis: Evaluation of Brain Damage and Clinical Implications. Mult Scler Int 2013; 2013: 671730 , Epub 2013 Mar 31
- 339 Filippi M, Tortorella C, Rovaris M , et al. Changes in the normal appearing brain tissue and cognitive impairment in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000; 68 (2) 157-161
- 340 Cercignani M, Inglese M, Pagani E, Comi G, Filippi M. Mean diffusivity and fractional anisotropy histograms of patients with multiple sclerosis. AJNR Am J Neuroradiol 2001; 22 (5) 952-958
- 341 Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M. Quantification of brain gray matter damage in different MS phenotypes by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 2002; 23 (6) 985-988
- 342 Vrenken H, Pouwels PJ, Geurts JJ , et al. Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: cortical diffusion changes seem related to clinical deterioration. J Magn Reson Imaging 2006; 23 (5) 628-636
- 343 Ceccarelli A, Rocca MA, Valsasina P , et al. A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis. Hum Brain Mapp 2009; 30 (9) 3009-3019
- 344 Preziosa P, Rocca MA, Mesaros S , et al. Intrinsic damage to the major white matter tracts in patients with different clinical phenotypes of multiple sclerosis: a voxelwise diffusion-tensor MR study. Radiology 2011; 260 (2) 541-550
- 345 Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999; 122 (Pt 1) 17-26
- 346 Bobholz JA, Rao SM, Lobeck L , et al. fMRI study of episodic memory in relapsing-remitting MS: correlation with T2 lesion volume. Neurology 2006; 67 (9) 1640-1645
- 347 Chiaravalloti N, Hillary F, Ricker J , et al. Cerebral activation patterns during working memory performance in multiple sclerosis using FMRI. J Clin Exp Neuropsychol 2005; 27 (1) 33-54
- 348 Mainero C, Caramia F, Pozzilli C , et al. fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis. Neuroimage 2004; 21 (3) 858-867
- 349 Staffen W, Mair A, Zauner H , et al. Cognitive function and fMRI in patients with multiple sclerosis: evidence for compensatory cortical activation during an attention task. Brain 2002; 125 (Pt 6) 1275-1282
- 350 Wishart HA, Saykin AJ, McDonald BC , et al. Brain activation patterns associated with working memory in relapsing-remitting MS. Neurology 2004; 62 (2) 234-238
- 351 Genova HM, Hillary FG, Wylie G, Rypma B, Deluca J. Examination of processing speed deficits in multiple sclerosis using functional magnetic resonance imaging. J Int Neuropsychol Soc 2009; 15 (3) 383-393
- 352 Nebel K, Wiese H, Seyfarth J , et al. Activity of attention related structures in multiple sclerosis patients. Brain Res 2007; 1151: 150-160
- 353 Penner IK, Rausch M, Kappos L, Opwis K, Radü EW. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003; Jul; 250 (4) 461-472
- 354 Filippi M, Agosta F, Spinelli EG, Rocca MA. Imaging resting state brain function in multiple sclerosis. J Neurol 2013; Jul; 260 (7) 1709-1713
- 355 Rocca MA, Absinta M, Filippi M. The role of advanced magnetic resonance imaging techniques in primary progressive MS. J Neurol 2012; 259 (4) 611-621
- 356 Rocca MA, Valsasina P, Martinelli V , et al. Large-scale neuronal network dysfunction in relapsing-remitting multiple sclerosis. Neurology 2012; 79 (14) 1449-1457
- 357 Faivre A, Rico A, Zaaraoui W , et al. Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis. Mult Scler 2012; 18 (9) 1251-1258
- 358 Hawellek DJ, Hipp JF, Lewis CM, Corbetta M, Engel AK. Increased functional connectivity indicates the severity of cognitive impairment in multiple sclerosis. Proc Natl Acad Sci U S A 2011; 108 (47) 19066-19071
- 359 Loitfelder M, Filippi M, Rocca M , et al. Abnormalities of resting state functional connectivity are related to sustained attention deficits in MS. PLoS ONE 2012; 7 (8) e42862
- 360 Bonavita S, Gallo A, Sacco R , et al. Distributed changes in default-mode resting-state connectivity in multiple sclerosis. Mult Scler 2011; 17 (4) 411-422
- 361 Sun X, Tanaka M, Kondo S, Okamoto K, Hirai S. Clinical significance of reduced cerebral metabolism in multiple sclerosis: a combined PET and MRI study. Ann Nucl Med 1998; 12 (2) 89-94
- 362 Paulesu E, Perani D, Fazio F , et al. Functional basis of memory impairment in multiple sclerosis: a[18F]FDG PET study. Neuroimage 1996; 4 (2) 87-96
- 363 Pozzilli C, Fieschi C, Perani D , et al. Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis. J Neurol Sci 1992; 112 (1-2) 51-57
- 364 Blinkenberg M, Jensen CV, Holm S, Paulson OB, Sørensen PS. A longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS. Neurology 1999; 53 (1) 149-153
- 365 Banati RB, Newcombe J, Gunn RN , et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; May; 123 (Pt 11) 2321-2337
- 366 Debruyne JC, Versijpt J, Van Laere KJ , et al. PET visualization of microglia in multiple sclerosis patients using [11C]PK11195. Eur J Neurol 2003; May; 10 (3) 257-264
- 367 Versijpt J, Debruyne JC, Van Laere KJ , et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study. Mult Scler 2005; 11 (2) 127-134
- 368 Politis M, Giannetti P, Su P , et al. Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 2012; 79 (6) 523-530
- 369 Chang L, Ernst T, Leonido-Yee M, Walot I, Singer E. Cerebral metabolite abnormalities correlate with clinical severity of HIV-1 cognitive motor complex. Neurology 1999; 52 (1) 100-108
- 370 Küper M, Rabe K, Esser S , et al. Structural gray and white matter changes in patients with HIV. J Neurol 2011; 258 (6) 1066-1075
- 371 Ragin AB, Du H, Ochs R , et al. Structural brain alterations can be detected early in HIV infection. Neurology 2012; 79 (24) 2328-2334
- 372 Thompson PM, Dutton RA, Hayashi KM , et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A 2005; 102 (43) 15647-15652
- 373 Chang L, Ernst T, Tornatore C , et al. Metabolite abnormalities in progressive multifocal leukoencephalopathy by proton magnetic resonance spectroscopy. Neurology 1997; 48 (4) 836-845
- 374 Mark AS, Atlas SW. Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images. Radiology 1989; 173 (2) 517-520
- 375 Paul RH, Ernst T, Brickman AM , et al; ACTG 301 team; ACTG 700 team; HIV MRS Consortium. Relative sensitivity of magnetic resonance spectroscopy and quantitative magnetic resonance imaging to cognitive function among nondemented individuals infected with HIV. J Int Neuropsychol Soc 2008; 14 (5) 725-733
- 376 Ragin AB, Storey P, Cohen BA, Epstein LG, Edelman RR. Whole brain diffusion tensor imaging in HIV-associated cognitive impairment. AJNR Am J Neuroradiol 2004; 25 (2) 195-200
- 377 Tate DF, Conley J, Paul RH , et al. Quantitative diffusion tensor imaging tractography metrics are associated with cognitive performance among HIV-infected patients. Brain Imaging Behav 2010; 4 (1) 68-79
- 378 Leite SC, Corrêa DG, Doring TM , et al. Diffusion tensor MRI evaluation of the corona radiata, cingulate gyri, and corpus callosum in HIV patients. J Magn Reson Imaging 2013;
- 379 Garvey LJ, Pavese N, Ramlackhansingh A , et al. Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS ONE 2012; 7 (7) e38980
- 380 Tucker KA, Robertson KR, Lin W , et al. Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol 2004; 157 (1-2) 153-162
- 381 Chang L, Speck O, Miller EN , et al. Neural correlates of attention and working memory deficits in HIV patients. Neurology 2001; 57 (6) 1001-1007
- 382 Ernst T, Chang L, Jovicich J, Ames N, Arnold S. Abnormal brain activation on functional MRI in cognitively asymptomatic HIV patients. Neurology 2002; 59 (9) 1343-1349
- 383 Maki PM, Cohen MH, Weber K , et al. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women: a preliminary study. Neurology 2009; 72 (19) 1661-1668
- 384 Melrose RJ, Tinaz S, Castelo JM, Courtney MG, Stern CE. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav Brain Res 2008; 188 (2) 337-347
- 385 Thomas JB, Brier MR, Snyder AZ, Vaida FF, Ances BM. Pathways to neurodegeneration: effects of HIV and aging on resting-state functional connectivity. Neurology 2013; 80 (13) 1186-1193
- 386 Chang L, Ernst T, Leonido-Yee M, Speck O. Perfusion MRI detects rCBF abnormalities in early stages of HIV-cognitive motor complex. Neurology 2000; 54 (2) 389-396
- 387 Maini CL, Pigorini F, Pau FM , et al. Cortical cerebral blood flow in HIV-1-related dementia complex. Nucl Med Commun 1990; 11 (9) 639-648
- 388 Tracey I, Hamberg LM, Guimaraes AR , et al. Increased cerebral blood volume in HIV-positive patients detected by functional MRI. Neurology 1998; 50 (6) 1821-1826
- 389 Rottenberg DA, Sidtis JJ, Strother SC , et al. Abnormal cerebral glucose metabolism in HIV-1 seropositive subjects with and without dementia. J Nucl Med 1996; Jul; 37 (7) 1133-1141
- 390 Rottenberg DA, Moeller JR, Strother SC , et al. The metabolic pathology of the AIDS dementia complex. Ann Neurol 1987; 22 (6) 700-706
- 391 Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR Am J Roentgenol 2011; 197 (2) 284-294
- 392 Pascal S, Resnick L, Barker WW , et al. Metabolic asymmetries in asymptomatic HIV-1 seropositive subjects: relationship to disease onset and MRI findings. J Nucl Med 1991; Sept; 32 (9) 1725-1729
- 393 Wang GJ, Chang L, Volkow ND , et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain 2004; 127 (Pt 11) 2452-2458
- 394 Ioannides P, Karacostas D. Neuroimaging in human prion disease: Searching in the mist. World J Radiol 2009; Dec 31; 1 (1) 45-49
- 395 Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jäger HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry 2007; 78 (7) 664-670
- 396 Puoti G, Bizzi A, Forloni G, Safar JG, Tagliavini F, Gambetti P. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol 2012; 11 (7) 618-628
- 397 Tschampa HJ, Kallenberg K, Urbach H , et al. MRI in the diagnosis of sporadic Creutzfeldt-Jakob disease: a study on inter-observer agreement. Brain 2005; 128 (Pt 9) 2026-2033
- 398 Schröter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol 2000; 57 (12) 1751-1757
- 399 Ukisu R, Kushihashi T, Kitanosono T , et al. Serial diffusion-weighted MRI of Creutzfeldt-Jakob disease. AJR Am J Roentgenol 2005; 184 (2) 560-566
- 400 Shiga Y, Miyazawa K, Sato S , et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology 2004; 63 (3) 443-449
- 401 Meissner B, Körtner K, Bartl M , et al. Sporadic Creutzfeldt-Jakob disease: magnetic resonance imaging and clinical findings. Neurology 2004; 63 (3) 450-456
- 402 Kim JH, Choi BS, Jung C, Chang Y, Kim S. Diffusion-weighted imaging and magnetic resonance spectroscopy of sporadic Creutzfeldt-Jakob disease: correlation with clinical course. Neuroradiology 2011; 53 (12) 939-945
- 403 Collie DA, Summers DM, Sellar RJ , et al. Diagnosing variant Creutzfeldt-Jakob disease with the pulvinar sign: MR imaging findings in 86 neuropathologically confirmed cases. AJNR Am J Neuroradiol 2003; 24 (8) 1560-1569
- 404 Zeidler M, Sellar RJ, Collie DA , et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet 2000; 355 (9213) 1412-1418
- 405 Will RG, Zeidler M, Stewart GE , et al. Diagnosis of new variant Creutzfeldt-Jakob disease. Ann Neurol 2000; 47 (5) 575-582
- 406 Pandya HG, Coley SC, Wilkinson ID, Griffiths PD. Magnetic resonance spectroscopic abnormalities in sporadic and variant Creutzfeldt-Jakob disease. Clin Radiol 2003; 58 (2) 148-153
- 407 Galanaud D, Haik S, Linguraru MG , et al. Combined diffusion imaging and MR spectroscopy in the diagnosis of human prion diseases. AJNR Am J Neuroradiol 2010; 31 (7) 1311-1318
- 408 de Silva R, Patterson J, Hadley D, Russell A, Turner M, Zeidler M. Single photon emission computed tomography in the identification of new variant Creutzfeldt-Jakob disease: case reports. BMJ 1998; 316 (7131) 593-594
- 409 Meissner B, Kallenberg K, Sanchez-Juan P , et al. MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease. J Neurol 2009; 256 (3) 355-363
- 410 García Santos JM, López Corbalán JA, Martínez-Lage JF, Sicilia Guillén JCT. CT and MRI in iatrogenic and sporadic Creutzfeldt-Jakob disease: as far as imaging perceives. Neuroradiology 1996; 38 (3) 226-231
- 411 du Plessis DG. Prion protein disease and neuropathology of prion disease. Neuroimaging Clin N Am 2008; 18 (1) 163-182 , ix ix
- 412 Fulbright RK, Hoffmann C, Lee H, Pozamantir A, Chapman J, Prohovnik I. MR imaging of familial Creutzfeldt-Jakob disease: a blinded and controlled study. AJNR Am J Neuroradiol 2008; 29 (9) 1638-1643
- 413 Wimberger D, Uranitsch K, Schindler E, Kramer J. Gerstmann-Sträussler-Scheinker syndrome: MR findings. J Comput Assist Tomogr 1993; 17 (2) 326-327
- 414 Arata H, Takashima H, Hirano R , et al. Early clinical signs and imaging findings in Gerstmann-Sträussler-Scheinker syndrome (Pro102Leu). Neurology 2006; 66 (11) 1672-1678
- 415 Aralasmak A, Crain BJ, Zou WQ, Yousem DM. A prion disease—possible Gerstmann-Straussler-Scheinker disease: a case report. J Comput Assist Tomogr 2006; 30 (1) 135-139
- 416 Waldman AD, Cordery RJ, MacManus DG, Godbolt A, Collinge J, Rossor MN. Regional brain metabolite abnormalities in inherited prion disease and asymptomatic gene carriers demonstrated in vivo by quantitative proton magnetic resonance spectroscopy. Neuroradiology 2006; 48 (6) 428-433
- 417 Konaka K, Kaido M, Okuda Y , et al. Proton magnetic resonance spectroscopy of a patient with Gerstmann-Straussler-Scheinker disease. Neuroradiology 2000; 42 (9) 662-665
- 418 Park MJ, Jo HY, Cheon SM, Choi SS, Kim YS, Kim JW. A case of gerstmann-sträussler-scheinker disease. J Clin Neurol 2010; 6 (1) 46-50
- 419 Zerr I, Giese A, Windl O , et al. Phenotypic variability in fatal familial insomnia (D178N-129M) genotype. Neurology 1998; 51 (5) 1398-1405
- 420 Almer G, Hainfellner JA, Brücke T , et al. Fatal familial insomnia: a new Austrian family. Brain 1999; 122 (Pt 1) 5-16
- 421 Lodi R, Parchi P, Tonon C , et al. Magnetic resonance diagnostic markers in clinically sporadic prion disease: a combined brain magnetic resonance imaging and spectroscopy study. Brain 2009; 132 (Pt 10) 2669-2679
- 422 Matoba M, Tonami H, Miyaji H, Yokota H, Yamamoto I. Creutzfeldt-Jakob disease: serial changes on diffusion-weighted MRI. J Comput Assist Tomogr 2001; 25 (2) 274-277
- 423 Montagna P, Gambetti P, Cortelli P, Lugaresi E. Familial and sporadic fatal insomnia. Lancet Neurol 2003; 2 (3) 167-176
- 424 Jagust WJ, Bandy D, Chen K , et al; Alzheimer's Disease Neuroimaging Initiative. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6 (3) 221-229
- 425 Swaminathan S, Shen L, Risacher SL , et al; Alzheimer's Disease Neuroimaging Initiative. Amyloid pathway-based candidate gene analysis of [(11)C]PiB-PET in the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort. Brain Imaging Behav 2012; Mar; 6 (1) 1-15
- 426 Risacher SL, Saykin AJ. Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection. Annu Rev Clin Psychol 2013; 9: 621-648
- 427 Kassubek J, Juengling FD, Kioschies T , et al. Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004; 75 (2) 213-220